Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ABEO
ABEO logo

ABEO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Abeona Therapeutics Inc (ABEO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.770
1 Day change
2.12%
52 Week Range
7.540
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, Abeona Therapeutics Inc (ABEO) does not currently present a compelling buy opportunity for a beginner investor with a long-term strategy. While the stock shows some bullish technical indicators, the lack of strong positive catalysts, news, or financial data, combined with neutral sentiment from hedge funds and insiders, suggests a cautious approach. The options data also does not indicate significant bullish sentiment.

Technical Analysis

The MACD is positive and expanding (0.00959), indicating bullish momentum. The RSI is neutral at 67.993, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 5.782 and 5.927, with support at 5.547 and 5.312. However, the stock's short-term trend suggests a 60% chance of a -0.8% drop in the next day and limited upside in the next week (0.66%) and month (3.21%).

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low Put-Call ratios indicate a bullish sentiment in options trading. However, the implied volatility is high (226.3), suggesting significant risk. The option volume today is below the 30-day average, indicating limited current interest.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
8

Positive Catalysts

  • Bullish technical indicators such as MACD and moving averages. Low Put-Call ratios in options data suggest some bullish sentiment.

Neutral/Negative Catalysts

  • No recent news or event-driven catalysts. Neutral sentiment from hedge funds and insiders. Lack of financial data and valuation metrics. No recent congress trading data.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data provided.

Wall Street analysts forecast ABEO stock price to rise
4 Analyst Rating
Wall Street analysts forecast ABEO stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.650
sliders
Low
20
Averages
25.17
High
28
Current: 5.650
sliders
Low
20
Averages
25.17
High
28
Alliance Global
Buy
downgrade
$20
AI Analysis
2026-03-17
Reason
Alliance Global
Price Target
$20
AI Analysis
2026-03-17
downgrade
Buy
Reason
Alliance Global lowered the firm's price target on Abeona Therapeutics to $20 from $27.50 and keeps a Buy rating on the shares following FY25 results. Alliance Global told investors in a research note that the company's earnings conference call focus included Zevaskyn's early launch progression, particularly the scale-up of Abeona Therapeutics' Qualified Treatment Center network to progress patient treatment. The firm noted that the price target cut accounts for its adjusted launch expectations of a more conservative launch trajectory.
Stifel
Stephen Willey
Buy
downgrade
$20 -> $19
2025-11-12
Reason
Stifel
Stephen Willey
Price Target
$20 -> $19
2025-11-12
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $19 from $20 and keeps a Buy rating on the shares. Management's temporary pause on patient biopsy collection sets back the commercial launch by about three months and decreases confidence in the firm's now-lower Q4 estimate as a result of the temporal uncertainty associated with the timing of revenue recognition, the analyst tells investors in a research note. The firm added that increasing patient demand strengthens its confidence in FY26 and beyond, and believes the set-up here offers an attractive risk/reward.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ABEO
Unlock Now

People Also Watch